Posts by: Eimear Galvin

HIHI National Director, Dr Colman Casey, makes the Professional 100, an annual listing of the Top 100 hospital professionals across Ireland

   |   By  |  0 Comments

Congratulations to HIHI National Director, Dr Colman Casey, makes the Professional 100, an annual listing of the Top 100 hospital professionals across Ireland. Dr Casey is in good company with such a breadth of talent across Irish healthcare, HIHI HSE Clinical Liaison Dr Diana Hogan-Murphy and recent graduate from the HIHI /TCD Postgraduate Diploma in Healthcare Innaviotn, Snr. Speech and Language Therapist at Cork University Hospital, Caitriona Heffernan.

Appearing in the December magazine, the annual list celebrates Ireland’s top hospital and healthcare achievers across a range of disciplines – healthcare to pharma industries, who act as ambassadors and role models for their peers and colleagues.

Editor of Hospital Professional News, Kelly-Jo Eastwood said:

“From working on the front-line in Ireland’s hospitals to contributing innovative research for the betterment of the profession, never has there been a more opportune time to recognise the unwavering excellence and dedication of Ireland’s hospital professionals.”

There was an outpouring of nominations throughout the sector and while each healthcare professional deserves to be recognised, the final list of professionals have displayed inspirational leadership affecting the development of hospital services across Ireland.”

More here:


Ibec launch: Ireland aims to be recognised as global hub for digital health

   |   By  |  0 Comments

Ireland has the potential to become a leader in the development of digital health solutions, attracting international investment and growth in high-tech indigenous companies. The claim is made as part of a new campaign- Where Digital Health Thrives- launched jointly by Ibec’s Irish Medtech Association, BioPharmaChem Ireland and Technology Ireland.

Digital health is the intersection of healthcare and technology and involves the innovative use of technology to deliver better patient care. The goal is to translate the benefits that technology has brought to other industries and bring them to healthcare, resulting in improved outcomes for patients and the providers of healthcare.

Where Digital Health Thrives aims to raise understanding of the potential of digital health, and Ireland’s potential to be a hub for its growth. The campaign was launched virtually today by Jim O’Donoghue, Chair of the Ibec Digital Health Working Group and President of S3 Connected Health.

Speaking at the launch, Mr O’Donoghue said;
Digital health is driving the personalisation of medicine and healthcare, putting the patient at the centre of their treatment in an informed and supported manner. Through connected devices, remote monitoring, apps and other technologies patients are empowered to manage their health and receive care in the right setting.

Digital health is supporting health care professionals by offering insights and providing them with new ways to support and treat patients. With data from connected devices HCPs can measure outcomes, personalise healthcare interventions and better connect with patients in multiple care settings.

This campaign is about demonstrating how Digital health can lower the cost of, and increase access to, healthcare. This not only leads to improved outcomes for patients and HCPs, but for payers and providers too.

Also speaking at the launch, Sharon Higgins, Director of Member Services in Ibec said;

We wanted to capture the scale and scope of the digital health ecosystem already here in Ireland, including nearly 200 companies already delivering digital health solutions such as telehealth, data, analytics and cyber security, health information technology, connected medtech, mobile health and many more.

Ireland is the 7th most competitive economy in the world. It is a location of choice to start and grow a business. Going Global from Ireland is in our DNA. Ireland is small open economy with a global outlook. We are a location of choice for FDI investment and home to world-class start-ups. Our business model is underscored by substance and has helped us achieve a global footprint. We can apply this to digital health by delivering solutions across boundaries and borders. Ireland’s unique ecosystem with leading digital health, medtech, pharma, and tech companies can make us a global digital health powerhouse.

Ibec is uniquely placed to support cross sectoral innovation and product commercialisation. The Irish Medtech Association, Technology Ireland and BioPharmaChem Ireland came together to develop and deliver this campaign which spans a publication, ecosystem map, digital collateral and networking events. Training will be delivered in partnership with Connected Health Skillnet, which was established in Ibec in 2017 to support the drive skills development in this area.


‘Design Thinking & Embedding a Culture of Innovation’: Dr Barry McMahon leads Module 2 in our Postgraduate Diploma in Healthcare Innovation

   |   By  |  0 Comments

On Friday and Saturday 6th and 7th of November Health Innovation Hub Ireland and TCD welcomed students to Module 2 of the Postgraduate Diploma in Healthcare Innovation (Level 9 NFQ).

Taking place online (due to ongoing government restrictions), the course was opened on Friday with welcome addresses from Dr Barry Mc Mahon, Chief Physicist/Clinical Associate (Clinical Medicine), Trinity College Dublin; Dr. John Dinsmore, Assistant Professor in Digital Integrated Care and the Health Innovation Lead of the Trinity Centre for Practice and Healthcare Innovation (TCPHI); and Professor Paul Coughlan, Professor in Operations Management and Director of Accreditation & Quality Assurance at Trinity Business School.

The objective of this module was to understand and use design thinking methodologies in a group environment to try to solve healthcare challenges. Creativity and design can be combined with knowledge and experience to accelerate and drive improvements in the delivery of healthcare. Students explored how healthcare organisations can develop and transform their services, their processes, and create new products ideas.

Working in teams, the students identified a healthcare challenge, developed a prototype solution, and finished the module with a pitch in front of a panel of Dr Barry McMahon, Dr John Dinsmore, Prof Paul Coughlan, Ann Quinn (Organisational and Development lead at Children’s Health Ireland), and Fran Hegarty (Chief Healthcare Technology Officer at New Children’s Hospital Dublin). Using these ‘real world’ challenges allows students the opportunity to develop critical thinking, creative problem solving, and visualisation methodologies.

More information on the HIHI/TCD Postgraduate Diploma in Healthcare Innovation can be found here or email Nina Holmes,


HIHI/HSE Health Innovation Champion Scholarships announced

  |   By  |  0 Comments

HIHI/HSE Health Innovation Champion Scholarships announced

 Today Health Innovation Hub Ireland (HIHI) announces the seven HSE staff who have been successful in gaining a scholarship place on the second year of the clinician led HIHI and Trinity College Dublin Postgraduate Diploma in Healthcare Innovation. From almost 50 applicants these seven, (detail in notes) were identified as high potential change makers in the Irish health system and offered a scholarship place among a class of health industry and health sector students.

A HSE and Enterprise Ireland partnership, HIHI holds a number of places for HSE scholarships, offering reduced fees. The aim is to reach right across levels, grades and disciplines in the health service offering the academic opportunity to all. The 2020/21 cohort of HIHI/HSE Health Innovation Champions come from organisations spanning the country – Cork, Dublin, Drogheda, Tullamore, Westmeath, Mayo and Donegal representing a diverse range of roles, departments and levels. These seven  are now part of an action focused learning community of 18, focused on accelerating change within their organisations. Over the 12-month programme, the students will complete eight modules, have access to workshops, resources and events to share challenges and experience, learn from expert guest lecturers.

Focusing on new health solutions, students gain a practical understanding of applying new technologies in healthcare.  Examining the role of health economics, quality improvement and the principles of governance in leading effective, innovative health services is a key learning. The postgraduate course culminates with modules seven and eight focusing on a practical project comprising two phases. Along with their fellow students, HIHI/HSE Innovation Champions will be supported to identify and implement  an innovative solution suitable for  each participant’s workplace, that will have a positive impact in Irish healthcare. As the HSE continues to respond to the COVID-19 pandemic, innovation – new ways of doing things – is  vital to the health sector.

Course Director Prof Seamas Donnelly said:

“Speaking as a clinician on the frontline, I know we need to adjust and reset some approaches in healthcare in Ireland and this postgraduate course is part of that effort. Our students are confident and inspirational leaders, learning to create their personal innovation framework to apply in healthcare organisations. All of our students share a common vision of creating an innovative healthcare system to change the system and improve outcomes for patients.

”The application process for this year’s Postgraduate Diploma in Healthcare Innovation was more competitive than ever, with a very high number of applications. I want to publically congratulate the outstanding applicants who have been accepted onto the programme.”

Sustained innovation in Irish healthcare, at an economically and fiscally responsible pace, must be a collaborative effort, requiring input from key players across the health landscape. HIHI and TCD recognise this and deliberately recruit students from both the health sector and the enterprise of health to the postgraduate diploma in healthcare innovation. The Postgraduate Diploma in Healthcare Innovation is currently delivered entirely online in keeping with government recommendations. Lectures will take place in TCD’s Tangent in the TCD business school on campus when these are lifted.


 HIHI/HSE Health Innovation Champion Scholarships awardees:

Name Title Organisation Location
Eleanor Campbell Clinical Specialist Radiographer in the Emergency Department (ED) Our Lady of Lourdes Hospital Drogheda
Antoinette Doherty Clinical nurse Specialist/ Advanced Nurse Prcatitioner CHO Area 1 Donegal
John Kelly Deputy CEO Tallaght University Hospital Dublin
Marie Prendergast Business Manager
Primary Care
Community Healthcare Organisation 2 Castlebar, Co Mayo
Niamh Gibney Senior Occupational Therapist Community Mental Health Centre Mullingar, Co. Westmeath
Eileen Lombard Senior Physiotherapist Mercy University Hospital Cork
Wishes to remain anonymous     Tullamore, Co Offaly

St James’ Hospital recruits patients with TB for Video Direct Observational Therapy study to investigate smartphone versus community care, in an Irish research first

   |   By  |  0 Comments

A Health Innovation Hub Ireland (HIHI) pilot study with St James’ Hospital will investigate the benefits of using technology against in person care in Tuberculosis (TB) medication adherence. In both the United Kingdom and the United States, the standard of care to ensure TB medication compliance is Video Direct Observational Therapy (VDOTS). The patient records a video ingesting medication remotely and submits securely via software to the TB nurse. Currently in Ireland, a community nurse physically visits a patient with TB medication adherence, watches each take their medication and records it manually on a hard copy – this is Direct Observational Therapy (DOT).

The public health nurse visits a patient’s home either once or twice a day, within the traditional DOT system for TB medication adherence,in use across Ireland depending on the treatment plan. By contrast, VDOTS uses a mobile smartphone application that allows patients to remotely record and send videos of every medication dose ingested. The nurse then views the date and time stamped videos on a secure web-based client management system (CMS) that is password protected. Once a patient’s videos are uploaded to the web portal, they are automatically deleted from the smartphone.

In 2018 in Ireland, there were 315 cases of TB notified with 38.4 per cent of total cases reported in Dublin. St James’ TB Clinical Nurse Specialist, Loraine Dolan approached HIHI to support the pilot study. The pilot will run for up to 18 months and test if VDOTS is superior to DOTS in recording doses of TB treatment that up to 40 Irish patients receive. The study will assess patient quality of life, cost effectiveness and resource efficiencies e.g. hours saved.  A similar UK study, published in The Lancet last year, found that the costs of providing DOT over six months were estimated at £5,700 per patient for observations five times per week and £3,420 for observations three times per week. For daily VOT over 6 months, costs were estimated at £1645 per patient.

Mary Day CEO St James’ Hospital said:

“As Irelands’ largest hospital, St James is committed to realising the full value of health technology and remote care to reduce the burden on the acute setting, achieve cost savings and empower our patients as active participants in their own care. We need this now more than ever.

“This HIHI/St James’ pilot has been driven by ingenuity on the frontline through Lorraine, with the invaluable support of Health Innovation Hub Ireland whose Dublin office is based here in St James Hospital.”

Eimear Galvin, HIHI TCD Manager said:

“Part of the HIHI national network is based in St James hospital, so we are very pleased to support this study and to have secured the software at no cost to the health service for the pilot duration.

“The need for remote care and patient management that technology such as this delivers is even more urgent now since Covid-19.  As a leader in digital health in Ireland, St James’ is the ideal site to test VDOT.”

Lorraine Dolan TB Nurse Specialist and study PI said:

“TB is a curable disease; however duration of treatment is lengthy ranging from six months to two years depending on the type and location of TB. The main aim of DOT is to ensure that patients take their medications each day and most importantly complete the treatment course.

“Although not a complete replacement for DOTs, VDOTS empowers patients who can engage with it, to live their lives normally without constraints and interruption to their working day or home life with a nurse visit. This HIHI/St James study will be the first to offer the VDOTS option to TB patients.”

TB remains a global health threat. In 2018, 1.5 million people died from TB. TB now ranks as the leading cause of death worldwide from an infectious agent, resulting in more deaths than HIV and malaria (WHO, 2019). Globally there were 10 million new cases of TB in 2018. Directly observed treatment (DOT) has been the standard of care for tuberculosis since the early 1990s, but in some cases can  be   inconvenient for patients and service providers. The use of VDOT has emerged in the last decade with the improvements in technology as an alternative approach in ensuring compliance with TB treatment.


Health Innovation Hub Ireland

HIHI has a remit from the Department of Business, Enterprise and Innovation, and the Department of Health to support business development and positively impact healthcare. HIHI recognises that collaboration with business can benefit patient care, patient pathways and outcomes. The hub’s national network connects innovative healthcare products with people qualified to test them, through usability, pilot and validation studies, supporting the development of new healthcare technologies and exposing the Irish health system to the latest innovative solutions. There are three hubs in the national network – Cork, Galway and Dublin.

 St James Hospital TB Centre

Established in St. James’s Hospital in 2004 the TB service comprises a multi-disciplinary team comprising of Consultant Respiratory Physicians, Registrar, TB Clinical Nurse Specialist, Senior Pharmacist, Public Health Doctors and Nurses, and administration staff work together.  Their aim is to ensure patients are seen efficiently, receive the appropriate TB investigations and treatment and support the patients to enable completion of treatment. Most patients with TB are treated as an outpatient. In Ireland, there were 315 cases of TB notified in 2018 with 38.4 per cent of total cases reported in Dublin (HSE, Health Protection surveillance Centre).

Lancet Study

Smartphone-enabled video-observed versus directly observed treatment for tuberculosis: a multicentre, analyst-blinded, randomised, controlled superiority trial (VOLUME 393, ISSUE 10177, P1216-1224, MARCH 23, 2019)



Enterprise Ireland Covid-19 Products Scheme now open – support for Irish based internationally focused companies

  |   By  |  0 Comments

Covid-19 Products Scheme

The COVID-19 outbreak has resulted in an urgent need across the EU and globally for medical and public health R&D, products and solutions. In response, The EU Temporary State Aid Framework has been amended to allow for, “the facilitation of research and development and expanded production into Coronavirus related products”.

The COVID-19 Products Scheme is composed of three measures, all of which aim to support Irish based internationally focused companies (SME and Large) to address:

  • Measure 1: COVID-19 relevant research and development (“R&D”) activities by companies coupled with the creation of useful IP.
  • Measure 2: The construction and upgrade of testing and upscaling infrastructures that are utilised to develop COVID-19 relevant products.
  • Measure 3: Increased production of products needed to respond to the COVID-19 outbreak. These outputs should be achieved as quickly as possible.

The scheme is time-limited and all funding must be approved by Enterprise Ireland no later than the 15th of December 2020. The scheme is now open for applications.

What are COVID-19 relevant products?

  • Relevant medicinal products (including vaccines) and treatments and their intermediates, active pharmaceutical ingredients and raw materials.
  • Medical devices and hospital and medical equipment, including PPE and necessary raw materials.
  • Disinfectants and their intermediary products and raw chemical materials necessary for their production.
  • Track and trace, temperature monitoring and relevant COVID-19 responsive services.
  • Process innovations targeting an efficient and streamlined production of the above.

Description of funding

This is a budget-limited scheme with the following features:

Measure 1

    • Max Grant Rate: up to 50% of qualifying costs
    • Max Grant: €650,000 per project

Measure 2 & 3

    • Max Grant Rate: up to 50% of qualifying costs
    • There is no upper limit to overall grant size (subject to budget)

Companies may make applications to all measures concurrently.

Key conditions of the scheme

  • General:
    • The scheme is open to COVID-19 relevant product activities only.
    • Retrospective costs (on or after the 1st February 2020): Where applicable, costs associated with activities of qualifying projects may be retrospectively funded. In these cases, the aid must assist projects which accelerate project implementation or extend project scope. The company must demonstrate to the satisfaction of Enterprise Ireland that costs were incurred on or after the 1st of February 2020.
    • Funding must be approved by Enterprise Ireland no later than the 15th of December 2020. The cut-off date for applications in line with the lifespan of the Scheme is the 30th November 2020.

• Measure 1:

    • Aid beneficiaries must commit to grant non-exclusive licences for any Intellectual Property (IP) generated by projects funded through the scheme under non-discriminatory market conditions to third parties in the European Economic Area (EEA).
  • Measure 2:
    • Resulting infrastructure cannot be predominately dedicated to one company; but instead consists of service providers that serve multiple users.
    • Project must be completed within 6 months of grant agreement being signed by the applicant. An investment project is considered completed when it is accepted by Enterprise Ireland as completed. Where the six-month deadline is not met, any payment under the grant agreement will be reduced by 25% of the amount of aid awarded per month of delay, unless the delay is due to factors outside the control of the aid beneficiary.
  • Measure 3:
    • Project must be completed within 6 months of grant agreement being signed by the applicant. An investment project is considered completed when it is accepted by Enterprise Ireland as completed. Where the six-month deadline is not met, any payment under the grant agreement will be reduced by 25% of the amount of aid awarded per month of delay, unless the delay is due to factors outside the control of the aid beneficiary.

Eligible companies

Key eligibility criteria are stated below. Further detailed information can be found in the Company Guidelines document for the scheme.

  • Employ 10 or more full-time employees*
  • Are operating in the manufacturing and internationally traded service sectors

Who cannot apply?

The scheme is not open to companies who:

  • Are active in the primary agricultural, fishery or aquaculture sectors.
  • Operate in the coal and steel sector.
  • Were covered by specific rules for Financial Services.

How to apply

Application forms are available from the Business Response Team within Enterprise Ireland, contact details for which are below:

• Email address:
• Telephone number:   +353 1 727 2088

All completed applications should be returned to the following inbox:

For further information

Enterprise Ireland has a comprehensive suite of supports available for companies at all stages of development, under Sustaining Enterprise Fund and Innovative Start-Up funding, as well as other funding offers.

If you have funding needs, please get in touch with your Development Adviser or our Covid 19 Business Response Unit at

Further detailed information on this scheme can be found in the Company Guidelines document.

Disruptive Technologies Innovation Fund Call 3 (2020) now open

  |   By  |  0 Comments


Enterprise Ireland will be hosting a DTIF Call 3 webinar on 22 October from 11am to 12 noon for those who are interested in learning more about the application process for DTIF Call 3.

The Disruptive Technologies Innovation Fund (DTIF) is a €500 million fund established under Project Ireland 2040 and is run by the Department of Business, Enterprise and Innovation with administrative support from Enterprise Ireland.

Disruptive Technologies Innovation Fund Call 3 (2020)

The Tánaiste and Minister for Enterprise, Trade and Employment, Leo Varadkar TD, launched the third Call for applications to the Disruptive Technologies Innovation Fund (DTIF) on 24 September 2020.

The deadline for receipt of applications is 17 December 2020 (15.00 Irish Time).

DTIF Call 3 – Main Points

The Disruptive Technologies Innovation Fund (DTIF) Call 3 is about funding collaborations that demonstrate technology-based disruptive innovation, collaborations that can:

  • Alter markets;
  • Alter the way business operates;
  • Involve new products or the emergence of new business models.

Funding applications for Call 3 should be within the Research Priority Areas 2018-2023. We are particularly interested in projects of scale with a strong enterprise agenda to harness maximum medium-term economic impact for Ireland. Ideally, we are looking for enterprise-driven research and development challenges that can demonstrate commercial impacts within 3 to 7 years of project completion.

As with Call 2, each project must have a minimum of three partners: two of these must be enterprise partners, at least one of which must be an SME. Research organisations (including colleges) can be a partner but can receive no more than 50% of the grant funding per project. All projects should be seeking minimum funding of €1.5 million. Small companies (less than 50 employees) that are part of successful applications under the Fund may be eligible for pre-finance subject to meeting conditions as set out in the Guide for Applicants.

Key amendments from Call 2 are:

  1. Change to one of the Selection Criterion, now called ‘Economic Impact and Sustainability’, to incorporate the commitment in the Climate Action Plan (CAP) for all National Development Plan (NDP) funds to prioritise the selection of low-carbon investments. Applicants are asked to demonstrate, as much as possible, positive contributions to the low carbon / sustainability targets in Ireland’s Climate Action Plan. Proposals funded under the DTIF should neither hinder the achievement of Ireland’s climate objectives nor have other significant negative environmental impacts.
  2. Economic impact outputs should be demonstrable within a 3 to 7-year timeframe (as opposed to the previous 3-5 years).

Guide for Applicants

Please see the DTIF Call 3 Guide for Applicants to learn more about applying for the Fund.

Each project partner in a collaborative partnership will be required to complete the attached Consortium Agreement template. 


Applications can be submitted online via the Enterprise Ireland website from one month before the application deadline of 17 December 2020. In the meantime, applicants can use this indicative application form to help prepare their application.

COVID-19 and the Disruptive Technologies Innovation Fund

The Department and Enterprise Ireland are aware that the current situation regarding the Coronavirus disease (COVID-19) may be having a significant impact on the research, development and innovation activities of companies and academic researchers.

We are working to understand the nature of any impacts on projects already funded through the Disruptive Technologies Innovation Fund (DTIF). We will try to facilitate any appropriate measures that may prove necessary, taking a flexible, constructive approach and we will consider any issues arising for projects on a case-by-case basis. Any queries should be directed to the DTIF team at Enterprise Ireland ( who will be happy to assist.

Please also consult the Department’s information on supports available for businesses impacted by COVID-19.

More here

New academic year, new HIHI Postgrad cohort, new ways of teaching – welcome innovation class of 2020/21

   |   By  |  0 Comments

Health Innovation Hub Ireland and TCD welcomed the 2020/21 Postgraduate Diploma in Healthcare Innovation (Level 9 NFQ) class on Friday 2 and Saturday 3. As with the inaugural year, students come from a wide range of healthcare backgrounds that will fortify the national network of healthcare innovators created by last years 2019/20 class.

Module one kicked off with a remote welcome from Course Director Prof Seamas Donnelly, Course Tutor Dan Maher and 2019/20 student Caitriona Heffernan, Senior Speech and Language Therapist, in the new home of the postgrad in Tangent on the TCD campus, though for now students are tuning in online.  HIHI National Director Colman Casey also spoke with the class offering a wide breath of knowledge of the innovation landscape in Ireland.

Guest speakers for Module One were Prof Brian Caulfield, leader of UCD’s connected health programme and Director of INSIGHT, and Conor Hanley, CEO of Irish scuccess story FIRE1, whose novel remote monitoring solution to improve outcomes for heart failure patients has raised millions in investor funding.

The first module in the Postgraduate Diploma in Healthcare Innovation examines the complex and rapidly changing world of global healthcare. A core focus is the dynamics of the quadruple helix (Government, Academia, Industry, Citizen/Patient) exploring the impact of disruptive innovation across each strand. The module takes this informed view of the present status of healthcare and begins exploring future innovations and directional trends.

More information on the HIHI/TCD Postgraduate Diploma in Healthcare Innovation can be found here or email Nina Holmes,

Today marks the official launch of HealthTech Ireland – the new name for the Irish Medical & Surgical Trade Association (IMSTA)

  |   By  |  0 Comments

The new name, HealthTech Ireland, better reflects the technological nature of what the members do, including the provision of digital, diagnostic and device solutions that help people live healthier lives. Visit the new website:

The rebranding reflects the determination of the representative body to continue to advocate for and promote the best in Irish health technology and the companies that produce, service and promote it.

Please note that email addresses will change from to . Learn more about the new name and brand identity here

HIHI clients lead Irish Startup consortium win of EU grant for COVID-19 Monitoring and Triaging Platform

  |   By  |  0 Comments

A consortium led by Think Biosolution, an Irish Medtech SME won a €150,000 grant from DIGI-B-CUBE call. Irish consortium partners Wellola and Think Biosolution are both clients of national innovation center Health Innovation Hub Ireland, which facilitated their connection. from Italy, and SYNYO Gmbh from Austria make up the remainder of the consortium. Together they will further develop and test EU’s first automated triaging platform for COVID-19 patients.

“In total, 217 applications from 470 SMEs were received by DIGI-B-CUBE. The applications cover 34 countries from all over Europe and its associated countries. After an intense review period of four weeks, a total of 17 applications were selected for funding. Eight projects got Prototyping Vouchers worth up to €60,000 per project, and nine projects for Customised Solution Innovation Vouchers are worth up to €150,000 per project.

In the current cohort, Customised Solution Innovation Vouchers were granted for topics like Sleep Apnea Test Device, COVID-19 Monitoring, and in vitro cellular immunoassays. The DIGI-B-CUBE call aim at unlocking the cross-sectoral collaborative potential of SMEs by combining novel digital technologies with the Bioimaging/Biosensing/Biobanking and related industries. The next and final cut-off date for the submission of customized solution innovation and prototyping vouchers is on 03 February 2021.” Said Dr. Udatha Gupta, Project Coordinator of DIGI-B-CUBE and Director (Digital & EU), Oslo Cancer Cluster, Oslo Norway.

“This DIGI-B-CUBE funding will be instrumental for us to launch our COVID-19 platform in the EU from a regulatory framework. Our strong consortium of partners will ensure that our platform is regulatory compliant as well as delivers value in terms of patient adherence and early warning score to At-Home COVID-19 patients”, said Dr. Shourjya Sanyal, Think Biosolution.

“Wellola is proud to collaborate with our partner, Think Biosolution, on such an innovative and exciting project; the outcome of which has the potential to deliver enormous clinical and economic benefit in multiple healthcare settings on a global scale”, added Sonia Neary, MD at Wellola.

Links –